Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PN-943 in moderate to severe active ulcerative colitis
2019-004469-41Phase 2Completed
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Mar 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PN-943 in autoimmune colitis (3 arms), sponsored by Protagonist Therapeutics, Inc. Primary endpoint: Efficacy. Started Mar 2020; status: completed.
02
Drugs
PN-943
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-004469-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004469-41.